Last updated: September 2, 2026
Surufatinib, also known as sulfatinib and HMPL-012, is an oral antiangiogenic kinase inhibitor developed by HUTCHMED for advanced neuroendocrine tumors. It is approved in China under the brand Sulanda for pancreatic and non-pancreatic neuroendocrine tumors. Its commercial value remains concentrated in China because the U.S. regulatory application received a complete response letter and no FDA approval has followed.
The base-case outlook is a China-focused specialty oncology product with modest but durable revenue growth. A successful U.S. resubmission or a new international development partnership would materially increase the opportunity, but that outcome is not reflected in the base case.
What is surufatinib and how does it work?
Surufatinib is a small-molecule inhibitor of vascular endothelial growth factor receptors 1, 2 and 3, fibroblast growth factor receptor 1, and colony-stimulating factor 1 receptor. The mechanism combines antiangiogenic activity with inhibition of tumor-associated macrophage signaling.
The drug is administered orally and is intended for patients with advanced, unresectable or metastatic neuroendocrine tumors after disease progression or where no satisfactory alternative exists. Its principal competitive distinction is activity across both pancreatic and non-pancreatic neuroendocrine tumor populations.
Which cancers is surufatinib being developed to treat?
The main development areas are:
- Pancreatic neuroendocrine tumors, or pNETs
- Non-pancreatic neuroendocrine tumors, or epNETs and other non-pancreatic NETs
- Advanced, progressive NETs after prior systemic therapy
- Potential combinations with immunotherapy or other targeted agents
Surufatinib is not a biologic. Biosimilar substitution is therefore not relevant. The principal future competition will come from small-molecule generics, branded targeted therapies and peptide receptor radionuclide therapy.
What is the current FDA status of surufatinib?
Surufatinib does not have FDA approval. HUTCHMED submitted a U.S. New Drug Application based primarily on the SANET-p and SANET-ep studies. The FDA accepted the application and assigned a target action date in 2022, but later issued a complete response letter.
The complete response letter prevented approval of the initial application. HUTCHMED subsequently reported discussions with the FDA regarding the deficiencies and the requirements for a potential resubmission. The public record has not established a new U.S. approval date.
| Regulatory event |
Date |
Status |
| China approval for non-pancreatic NETs |
December 2020 |
Approved |
| China approval for pancreatic NETs |
June 2021 |
Approved |
| U.S. NDA acceptance |
2022 |
Completed |
| U.S. complete response letter |
November 2022 |
Not approved |
| U.S. commercial launch |
Not available |
No FDA launch |
| EU approval |
Not available |
No approval identified |
| Japan approval |
Not available |
No approval identified |
The U.S. regulatory risk is the largest factor affecting valuation. A resubmission based only on administrative or manufacturing remediation could be relatively manageable. A requirement for additional confirmatory clinical data would extend the timeline and increase development cost.
What is the Orange Book status of surufatinib?
Surufatinib has no FDA-approved product listing and therefore does not have an Orange Book listing for U.S. reference-product purposes. Paragraph IV litigation cannot begin against a U.S. reference product until an approved NDA and listed patents exist.
The U.S. commercial protection strategy would likely rely on a combination of composition-of-matter, pharmaceutical composition, treatment-method and manufacturing patents. The practical value of those rights depends on their U.S. filing status, expiration dates, patent-term adjustment and any applicable regulatory exclusivity.
What clinical data support surufatinib?
The core evidence comes from two randomized Chinese phase III studies.
SANET-p in pancreatic neuroendocrine tumors
SANET-p evaluated surufatinib in patients with advanced, well-differentiated, progressive pNETs. The study reported a median progression-free survival of approximately 10.9 months with surufatinib versus 3.7 months with placebo. The hazard ratio for disease progression or death was approximately 0.49.
The results supported the Chinese approval for advanced pancreatic NETs. The trial demonstrated disease-control activity in a population with limited treatment options, but overall-survival interpretation was affected by crossover and the post-progression treatment landscape.
SANET-ep in non-pancreatic neuroendocrine tumors
SANET-ep evaluated patients with advanced, well-differentiated, progressive non-pancreatic NETs. Median progression-free survival was approximately 9.2 months with surufatinib versus 3.8 months with placebo. The hazard ratio was approximately 0.33.
The study included gastrointestinal and other non-pancreatic NET populations. The magnitude of progression-free survival benefit was clinically meaningful, but regulatory transferability outside China depends on site inspection, data verification, population representativeness and the FDA's assessment of trial conduct.
| Trial |
Population |
Surufatinib median PFS |
Control median PFS |
Hazard ratio |
| SANET-p |
Advanced pancreatic NET |
10.9 months |
3.7 months |
0.49 |
| SANET-ep |
Advanced non-pancreatic NET |
9.2 months |
3.8 months |
0.33 |
Sources: Xu et al. (2020a, 2020b).
What is the China commercial status of surufatinib?
China is the only established commercial market. HUTCHMED markets surufatinib through its China oncology infrastructure, with access shaped by hospital listing, provincial reimbursement, physician familiarity and the availability of competing NET treatments.
The product competes with:
- Everolimus, marketed by Novartis
- Sunitinib, marketed by Pfizer
- Somatostatin analogues, including octreotide and lanreotide
- Peptide receptor radionuclide therapy, including lutetium-177-based products
- Cytotoxic chemotherapy in selected aggressive or high-burden disease
- Increasingly available domestic targeted therapies
Surufatinib's China positioning is strongest in progressive, well-differentiated NETs where antiangiogenic treatment is clinically appropriate and physicians seek an oral option. Reimbursement and treatment sequencing remain more important than label breadth.
How does surufatinib compare with everolimus and sunitinib?
| Attribute |
Surufatinib |
Everolimus |
Sunitinib |
| Primary target profile |
VEGFR, FGFR1, CSF1R |
mTOR |
VEGFR and other kinases |
| Route |
Oral |
Oral |
Oral |
| Main NET use |
Pancreatic and non-pancreatic NETs in China |
Pancreatic, gastrointestinal and lung NETs in many markets |
Pancreatic NETs |
| Key evidence |
SANET-p and SANET-ep |
RADIANT program |
Phase III pNET study |
| China status |
Approved |
Approved |
Approved |
| U.S. status |
Not approved |
Approved |
Approved |
| Differentiation |
Broad NET development and dual antiangiogenic/immunologic rationale |
Established global label |
Established pNET use |
Cross-trial comparisons are unreliable because the studies used different populations, prior-treatment requirements, endpoints and control arms. Surufatinib's strongest evidence is its consistent progression-free survival benefit in two separate NET settings.
When does surufatinib lose exclusivity?
No single global expiration date should be used for surufatinib. Exclusivity depends on the jurisdiction and on which patent family is being analyzed.
What patents protect surufatinib?
The relevant protection categories are expected to include:
- Active pharmaceutical ingredient and chemical composition
- Salt, polymorph and crystalline forms
- Pharmaceutical compositions
- Oral dosage forms
- Treatment of neuroendocrine tumors
- Combination treatment with other anticancer agents
- Synthetic processes and intermediates
HUTCHMED and affiliated entities have been associated with the development and commercialization of surufatinib. Because the product has no U.S. approval, there is no Orange Book patent set against which a U.S. generic applicant could currently file a Paragraph IV certification.
China patent enforcement remains commercially relevant. A Chinese generic or domestic competitor could face composition, formulation or method-of-use barriers, although the actual risk depends on claim scope and enforceability. The first generic-entry risk is therefore likely to arise in China rather than the United States.
What formulation and manufacturing barriers affect generic entry?
Surufatinib is an oral small molecule, so its manufacturing barrier is lower than that of a biologic or complex injectable product. The principal barriers are:
- Demonstrating pharmaceutical equivalence and bioequivalence
- Reproducing dissolution and impurity specifications
- Establishing access to active pharmaceutical ingredient manufacturing
- Avoiding valid composition and process claims
- Meeting China National Medical Products Administration requirements
- Securing hospital and reimbursement access
Manufacturing IP can delay entry but is less likely to provide a durable barrier than a valid composition-of-matter patent. Method-of-use claims may have commercial value where prescribing is concentrated in the protected indication, but they are more difficult to enforce against generic substitution.
Which companies are challenging surufatinib?
No U.S. Paragraph IV challenger or U.S. patent litigation program has been publicly established because the product is not FDA approved.
Competitive pressure is more likely to come from established NET products and Chinese oncology developers than from a direct generic challenge in the near term. Relevant competitors include Novartis, Pfizer, Ipsen, Advanced Accelerator Applications, and Chinese companies developing targeted therapies, radioligand treatments and next-generation antiangiogenic agents.
A direct China generic challenge would become more likely if:
- Product volume increases materially
- Key composition patents expire or are invalidated
- Reimbursement expands the addressable patient population
- The product achieves a stronger position in treatment guidelines
- HUTCHMED's China pricing supports an attractive generic market
What licensing deals affect surufatinib?
HUTCHMED entered a global collaboration with Takeda Pharmaceutical to develop and commercialize surufatinib outside China. Takeda later ended the collaboration, returning ex-China rights to HUTCHMED.
The termination reduced the probability of a rapid multinational launch and shifted regulatory, financing and commercial execution responsibility back to HUTCHMED. It also created a potential partnering asset if U.S. regulatory issues are resolved or if new data support development in Europe or Japan.
No active global commercial partnership with a major multinational has been established in the public record comparable to the former Takeda arrangement.
What is the market projection for surufatinib?
The base-case market is China, with a smaller probability-weighted international opportunity.
Base-case projection: China only
A reasonable commercial model assumes gradual uptake in advanced NETs, constrained by competition, reimbursement and physician sequencing. Under that framework:
| Year |
Base-case China net sales estimate |
Main assumption |
| 2024 |
$60 million-$90 million |
Established China use with reimbursement constraints |
| 2025 |
$70 million-$105 million |
Wider hospital penetration |
| 2026 |
$80 million-$120 million |
Stable prescribing and improved access |
| 2027 |
$85 million-$130 million |
Mature China specialty-product position |
| 2028-2030 |
$90 million-$150 million annually |
Growth offset by competition and price pressure |
These are analytical estimates, not reported company guidance. The model assumes continued Chinese availability, no major safety signal, stable labeling and no rapid generic erosion.
Upside case: successful U.S. development
If HUTCHMED obtains a viable U.S. regulatory path, a U.S. launch could expand the addressable market substantially. A successful pathway would require:
- Resolution of FDA deficiencies
- Acceptance of a resubmitted NDA or a new application
- An adequate label for pancreatic and/or non-pancreatic NETs
- Commercial reimbursement
- A U.S. sales partner or expanded HUTCHMED infrastructure
Under an approval scenario, peak U.S. sales could reach approximately $150 million-$300 million, depending on the label and competitive positioning. Global annual sales could then approach $250 million-$450 million at peak. The high end requires a broad label, meaningful use after progression and limited patent or generic erosion.
Downside case
The downside case is continued U.S. non-approval, slow China uptake and earlier-than-expected price pressure. Under that scenario, annual sales may remain below $75 million-$100 million, with the product functioning as a niche China oncology asset rather than a global growth driver.
How strong is the surufatinib patent estate?
The estate is commercially adequate for a China-focused product but strategically incomplete without a clear U.S. regulatory pathway. Patent strength should be assessed on four factors:
- Remaining term for core composition claims
- Geographic coverage outside China
- Validity and enforceability of treatment-method claims
- Ability to block an equivalent oral generic rather than only a narrow formulation
The absence of an FDA approval and Orange Book listing limits U.S. litigation leverage. A future U.S. launch would require a refreshed patent and exclusivity strategy, including FDA listing, patent-term review and potential pediatric or other regulatory exclusivity.
What generic launch risks exist for surufatinib?
The near-term risk is moderate in China and low in the United States because there is no approved U.S. reference product.
China risks include:
- Domestic competitors developing equivalent products
- Price reductions through centralized or provincial procurement
- Off-label or label-expanding competition from established NET drugs
- Reduced use after availability of radioligand therapy
- Patent invalidation or narrow claim construction
- Physician preference for products with longer international experience
The most likely generic launch scenario is a China-only entrant after the expiration or weakening of core Chinese patent protection. A U.S. generic launch is not a near-term scenario without FDA approval and an approved reference product.
Key Takeaways
- Surufatinib is approved in China for advanced pancreatic and non-pancreatic NETs.
- SANET-p and SANET-ep produced substantial progression-free survival benefits.
- The FDA issued a complete response letter, and surufatinib remains unapproved in the United States.
- Takeda's exit returned global rights outside China to HUTCHMED.
- China is the only established commercial market.
- Base-case annual China sales are approximately $90 million-$150 million at maturity.
- Successful U.S. development could raise peak global sales toward $250 million-$450 million.
- No U.S. Orange Book listing or Paragraph IV litigation currently applies.
- The product is more exposed to reimbursement, competition and regulatory execution than to biosimilar risk.
- The strongest commercial value driver is a credible U.S. regulatory resubmission supported by FDA-acceptable clinical and manufacturing data.
FAQs
Is surufatinib approved outside China?
No major approval outside China has been established in the cited public record. China remains the product's principal and only established commercial market.
Is surufatinib a VEGFR inhibitor?
Yes. Surufatinib inhibits VEGFR1, VEGFR2 and VEGFR3 and also acts against FGFR1 and CSF1R.
Can surufatinib compete with lutetium-177 DOTATATE?
Yes, but the products occupy different treatment positions. Surufatinib is an oral kinase inhibitor, while lutetium-177 DOTATATE is a radioligand therapy requiring suitable somatostatin-receptor expression and specialized treatment infrastructure.
Does surufatinib have biosimilar competition?
No. Surufatinib is a small-molecule drug, so the relevant future competitors are chemical generics and other branded oncology products.
What would most increase surufatinib's valuation?
The largest potential catalyst is a successful FDA resubmission leading to approval in the United States. A global licensing deal, broader international clinical data or stronger Chinese reimbursement could also improve the asset's commercial value.
References
-
HUTCHMED. (2022). Annual report 2021. HUTCHMED International Limited.
-
HUTCHMED. (2023). Annual report 2022. HUTCHMED International Limited.
-
HUTCHMED. (2023, November). HUTCHMED reports FDA complete response letter for surufatinib NDA. HUTCHMED International Limited.
-
National Medical Products Administration. (2020). Approval of surufatinib for advanced non-pancreatic neuroendocrine tumors. NMPA.
-
National Medical Products Administration. (2021). Approval of surufatinib for advanced pancreatic neuroendocrine tumors. NMPA.
-
Xu, J., Shen, L., Bai, C., Wang, W., Li, J., Yu, Y., et al. (2020a). Surufatinib in advanced pancreatic neuroendocrine tumors: A randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 21(11), 1489-1499.
-
Xu, J., Shen, L., Bai, C., Wang, W., Li, J., Yu, Y., et al. (2020b). Surufatinib in advanced non-pancreatic neuroendocrine tumors: A randomized, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 21(11), 1500-1512.
-
U.S. Food and Drug Administration. (2022). Complete response letters and regulatory correspondence for surufatinib. FDA.